DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy

Abstract

Treating macaques with an anti-α4β7 antibody under the umbrella of combination antiretroviral therapy (cART) during early SIV infection can lead to viral remission, with viral loads maintained at < 50 SIV RNA copies/ml after removal of all treatment in a subset of animals. Depletion of CD8+ lymphocytes in controllers resulted in transient recrudescence of viremia, suggesting that the combination of cART and anti-α4β7 antibody treatment led to a state where ongoing immune responses kept the virus undetectable in the absence of treatment. A previous mathematical model of HIV infection and cART incorporates immune effector cell responses and exhibits the property of two different viral load set-points. While the lower set-point could correspond to the attainment of long-term viral remission, attaining the higher set-point may be the result of viral rebound. Here we expand that model to include possible mechanisms of action of an anti-α4β7 antibody operating in these treated animals. We show that the model can fit the longitudinal viral load data from both IgG control and anti-α4β7 antibody treated macaques, suggesting explanations for the viral control associated with cART and an anti-α4β7 antibody treatment. This effective perturbation to the virus-host interaction can also explain observations in other nonhuman primatemore » experiments in which cART and immunotherapy have led to post-treatment control or resetting of the viral load set-point. Interestingly, because the viral kinetics in the various treated animals differed—some animals exhibited large fluctuations in viral load after cART cessation—the model suggests that anti-α4β7 treatment could act by different primary mechanisms in different animals and still lead to post-treatment viral control. This outcome is nonetheless in accordance with a model with two stable viral load set-points, in which therapy can perturb the system from one set-point to a lower one through different biological mechanisms.« less

Authors:
ORCiD logo [1]; ORCiD logo [2]; ORCiD logo [1]; ORCiD logo [3];  [4];  [1]; ORCiD logo [5]; ORCiD logo [6]; ORCiD logo [7]
  1. Yale School of Public Health, New Haven, CT (United States)
  2. Merck & Co., Inc., Kenilworth, NJ (United States); Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
  3. Univ. of Nebraska Medical Center, Omaha, NE (United States)
  4. Amory Univ. School of Medicine, Atlanta, GA (United States)
  5. Yale Univ., New Haven, CT (United States)
  6. Yale School of Public Health, New Haven, CT (United States); Yale Univ., New Haven, CT (United States)
  7. Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
Publication Date:
Research Org.:
Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
Sponsoring Org.:
National Institutes of Health (NIH); USDOE
OSTI Identifier:
1828708
Report Number(s):
LA-UR-20-20333
Journal ID: ISSN 1553-7358
Grant/Contract Number:  
89233218CNA000001; R01-OD011095; R01-AI028433; P01-AI131365; R01-AI29745
Resource Type:
Accepted Manuscript
Journal Name:
PLoS Computational Biology (Online)
Additional Journal Information:
Journal Name: PLoS Computational Biology (Online); Journal Volume: 17; Journal Issue: 6; Journal ID: ISSN 1553-7358
Publisher:
Public Library of Science
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; HIV; Post treatment control; viral kinetic model; Effector cell response; Latent reservoir

Citation Formats

Wells, Chad R., Cao, Youfang, Durham, David P., Byrareddy, Siddappa N., Ansari, Aftab A., Ruddle, Nancy H., Townsend, Jeffrey P., Galvani, Alison P., and Perelson, Alan S. Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy. United States: N. p., 2021. Web. doi:10.1371/journal.pcbi.1009031.
Wells, Chad R., Cao, Youfang, Durham, David P., Byrareddy, Siddappa N., Ansari, Aftab A., Ruddle, Nancy H., Townsend, Jeffrey P., Galvani, Alison P., & Perelson, Alan S. Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy. United States. https://doi.org/10.1371/journal.pcbi.1009031
Wells, Chad R., Cao, Youfang, Durham, David P., Byrareddy, Siddappa N., Ansari, Aftab A., Ruddle, Nancy H., Townsend, Jeffrey P., Galvani, Alison P., and Perelson, Alan S. Wed . "Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy". United States. https://doi.org/10.1371/journal.pcbi.1009031. https://www.osti.gov/servlets/purl/1828708.
@article{osti_1828708,
title = {Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy},
author = {Wells, Chad R. and Cao, Youfang and Durham, David P. and Byrareddy, Siddappa N. and Ansari, Aftab A. and Ruddle, Nancy H. and Townsend, Jeffrey P. and Galvani, Alison P. and Perelson, Alan S.},
abstractNote = {Treating macaques with an anti-α4β7 antibody under the umbrella of combination antiretroviral therapy (cART) during early SIV infection can lead to viral remission, with viral loads maintained at < 50 SIV RNA copies/ml after removal of all treatment in a subset of animals. Depletion of CD8+ lymphocytes in controllers resulted in transient recrudescence of viremia, suggesting that the combination of cART and anti-α4β7 antibody treatment led to a state where ongoing immune responses kept the virus undetectable in the absence of treatment. A previous mathematical model of HIV infection and cART incorporates immune effector cell responses and exhibits the property of two different viral load set-points. While the lower set-point could correspond to the attainment of long-term viral remission, attaining the higher set-point may be the result of viral rebound. Here we expand that model to include possible mechanisms of action of an anti-α4β7 antibody operating in these treated animals. We show that the model can fit the longitudinal viral load data from both IgG control and anti-α4β7 antibody treated macaques, suggesting explanations for the viral control associated with cART and an anti-α4β7 antibody treatment. This effective perturbation to the virus-host interaction can also explain observations in other nonhuman primate experiments in which cART and immunotherapy have led to post-treatment control or resetting of the viral load set-point. Interestingly, because the viral kinetics in the various treated animals differed—some animals exhibited large fluctuations in viral load after cART cessation—the model suggests that anti-α4β7 treatment could act by different primary mechanisms in different animals and still lead to post-treatment viral control. This outcome is nonetheless in accordance with a model with two stable viral load set-points, in which therapy can perturb the system from one set-point to a lower one through different biological mechanisms.},
doi = {10.1371/journal.pcbi.1009031},
journal = {PLoS Computational Biology (Online)},
number = 6,
volume = 17,
place = {United States},
year = {Wed Jun 09 00:00:00 EDT 2021},
month = {Wed Jun 09 00:00:00 EDT 2021}
}

Works referenced in this record:

Immune control of HIV-1 after early treatment of acute infection
journal, September 2000

  • Rosenberg, Eric S.; Altfeld, Marcus; Poon, Samuel H.
  • Nature, Vol. 407, Issue 6803
  • DOI: 10.1038/35035103

The V2 loop of HIV gp120 delivers costimulatory signals to CD4 + T cells through Integrin α 4 β 7 and promotes cellular activation and infection
journal, December 2020

  • Goes, Livia R.; Sajani, Alia; Sivro, Aida
  • Proceedings of the National Academy of Sciences, Vol. 117, Issue 51
  • DOI: 10.1073/pnas.2011501117

Estimating Heterogeneous Treatment Effects with Observational Data
journal, August 2012


Target Cell Limited and Immune Control Models of HIV Infection: A Comparison
journal, February 1998

  • De Boer, R. J.; Perelson, A. S.
  • Journal of Theoretical Biology, Vol. 190, Issue 3
  • DOI: 10.1006/jtbi.1997.0548

Residual Viremia in Treated HIV+ Individuals
journal, January 2016


Drug concentration heterogeneity facilitates the evolution of drug resistance
journal, September 1998

  • Kepler, T. B.; Perelson, A. S.
  • Proceedings of the National Academy of Sciences, Vol. 95, Issue 20
  • DOI: 10.1073/pnas.95.20.11514

Effect of 1918 PB1-F2 Expression on Influenza A Virus Infection Kinetics
journal, February 2011


CD8+ lymphocyte control of SIV infection during antiretroviral therapy
journal, October 2018


Lack of therapeutic efficacy of an antibody to α 4 β 7 in SIVmac251-infected rhesus macaques
journal, September 2019


Preliminary in vivo efficacy studies of a recombinant rhesus anti-α4β7 monoclonal antibody
journal, January 2009


Antagonizing the α 4 β 1 Integrin, but Not α 4 β 7 , Inhibits Leukocytic Infiltration of the Central Nervous System in Rhesus Monkey Experimental Autoimmune Encephalomyelitis
journal, January 2013

  • Haanstra, Krista G.; Hofman, Sam O.; Lopes Estêvão, Dave M.
  • The Journal of Immunology, Vol. 190, Issue 5
  • DOI: 10.4049/jimmunol.1202490

Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection
journal, November 2014

  • Byrareddy, Siddappa N.; Kallam, Brianne; Arthos, James
  • Nature Medicine, Vol. 20, Issue 12
  • DOI: 10.1038/nm.3715

Complement opsonization of HIV ‐1 results in a different intracellular processing pattern and enhanced MHC class I presentation by dendritic cells
journal, April 2013

  • Tjomsland, Veronica; Ellegård, Rada; Burgener, Adam
  • European Journal of Immunology, Vol. 43, Issue 6
  • DOI: 10.1002/eji.201242935

Replication challenges
journal, September 2019


On the Volume of Distribution at Steady State and Its Relationship With Two‐Compartmental Models
journal, January 2008

  • Yates, James W. T.; Arundel, Philip A.
  • Journal of Pharmaceutical Sciences, Vol. 97, Issue 1
  • DOI: 10.1002/jps.21089

Quantifying T lymphocyte turnover
journal, June 2013


The integrin  4 7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1
journal, November 2009

  • Cicala, C.; Martinelli, E.; McNally, J. P.
  • Proceedings of the National Academy of Sciences, Vol. 106, Issue 49
  • DOI: 10.1073/pnas.0911796106

A high throughput lentivirus sieving assay identifies neutralization resistant Envelope sequences and predicts in vivo sieving
journal, January 2019


Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques
journal, November 2007

  • Chen, H. Y.; Di Mascio, M.; Perelson, A. S.
  • Proceedings of the National Academy of Sciences, Vol. 104, Issue 48
  • DOI: 10.1073/pnas.0707449104

Modeling Plasma Virus Concentration during Primary HIV Infection
journal, April 2000

  • Stafford, Max A.; Corey, Lawrence; Cao, Yunzhen
  • Journal of Theoretical Biology, Vol. 203, Issue 3
  • DOI: 10.1006/jtbi.2000.1076

A brief guide to model selection, multimodel inference and model averaging in behavioural ecology using Akaike’s information criterion
journal, August 2010

  • Symonds, Matthew R. E.; Moussalli, Adnan
  • Behavioral Ecology and Sociobiology, Vol. 65, Issue 1
  • DOI: 10.1007/s00265-010-1037-6

Current Estimates for HIV-1 Production Imply Rapid Viral Clearance in Lymphoid Tissues
journal, September 2010


Model selection in ecology and evolution
journal, February 2004


NK cell exhaustion: bad news for chronic disease?
journal, August 2015

  • Schafer, Jamie L.; Müller-Trutwin, Michaela C.; Reeves, R. Keith
  • Oncotarget, Vol. 6, Issue 26
  • DOI: 10.18632/oncotarget.5490

Early antibody therapy can induce long-lasting immunity to SHIV
journal, March 2017

  • Nishimura, Yoshiaki; Gautam, Rajeev; Chun, Tae-Wook
  • Nature, Vol. 543, Issue 7646
  • DOI: 10.1038/nature21435

Turnover of CD4 + and CD8 + T Lymphocytes in HIV-1 Infection as Measured by Ki-67 Antigen
journal, April 1998

  • Sachsenberg, Nicolas; Perelson, Alan S.; Yerly, Sabine
  • The Journal of Experimental Medicine, Vol. 187, Issue 8
  • DOI: 10.1084/jem.187.8.1295

Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis
journal, November 1999


Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
journal, May 2015


Neutralizing and Targeting Properties of a New Set of α4β7-Specific Antibodies Are Influenced by Their Isotype
journal, January 2017

  • Girard, Alexandre; Jelicic, Katija; Van Ryk, Don
  • JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 75, Issue 1
  • DOI: 10.1097/QAI.0000000000001307

Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration
journal, July 2017


A Simian Immunodeficiency Virus-Infected Macaque Model To Study Viral Reservoirs That Persist during Highly Active Antiretroviral Therapy
journal, July 2009

  • Dinoso, J. B.; Rabi, S. A.; Blankson, J. N.
  • Journal of Virology, Vol. 83, Issue 18
  • DOI: 10.1128/JVI.00840-09

Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection
journal, July 2016


Blocking α 4 β 7 integrin binding to SIV does not improve virologic control
journal, September 2019


Kinetics of Virus-Specific CD8+ T Cells and the Control of Human Immunodeficiency Virus Infection
journal, August 2004


HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells
journal, February 2008

  • Arthos, James; Cicala, Claudia; Martinelli, Elena
  • Nature Immunology, Vol. 9, Issue 3
  • DOI: 10.1038/ni1566

Molecular and cellular insights into T cell exhaustion
journal, July 2015

  • Wherry, E. John; Kurachi, Makoto
  • Nature Reviews Immunology, Vol. 15, Issue 8
  • DOI: 10.1038/nri3862

High-Potency Human Immunodeficiency Virus Vaccination Leads to Delayed and Reduced CD8+ T-Cell Expansion but Improved Virus Control
journal, August 2005


Treatment-Mediated Alterations in HIV Fitness Preserve CD4+ T Cell Counts but Have Minimal Effects on Viral Load
journal, November 2010


The Efficiency of the Human CD8+ T Cell Response: How Should We Quantify It, What Determines It, and Does It Matter?
journal, February 2012

  • Elemans, Marjet; Seich al Basatena, Nafisa-Katrin; Asquith, Becca
  • PLoS Computational Biology, Vol. 8, Issue 2
  • DOI: 10.1371/journal.pcbi.1002381

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α 4 β 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
journal, June 2009

  • Soler, Dulce; Chapman, Tobias; Yang, Li-Li
  • Journal of Pharmacology and Experimental Therapeutics, Vol. 330, Issue 3
  • DOI: 10.1124/jpet.109.153973

Sustained virologic control in SIV+ macaques after antiretroviral and  4 7 antibody therapy
journal, October 2016


CD8 + Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy
journal, September 2016


Evaluation of an antibody to α 4 β 7 in the control of SIVmac239- nef-stop infection
journal, September 2019


Virion incorporation of integrin α4β7 facilitates HIV-1 infection and intestinal homing
journal, May 2017


PD-1 Expression on Natural Killer Cells and CD8 + T Cells During Chronic HIV-1 Infection
journal, August 2012

  • Norris, Sonia; Coleman, Adam; Kuri-Cervantes, Leticia
  • Viral Immunology, Vol. 25, Issue 4
  • DOI: 10.1089/vim.2011.0096

Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
journal, April 2019